Top Insights
Eli Lilly’s Morphic acquisition brings an oral small molecule that blocks the same target as Entvyio, an injectable inflammatory bowel disease drug from Takeda Pharmaceutical. The Morphic deal follows Lilly’s 2023 acquisition of Dice Therapeutics, another company developing oral immunology medications.
The post Eli Lilly Shows Appetite for Oral Immunology Drugs, Swallowing Morphic in $3.2B Deal appeared first on MedCity News.
Related Articles
Top Hospitals for Pacemaker Implantation Surgery in India: What you need to know?
Pacemaker implantation is a life-saving procedure for people with irregular heart rhythms....
Links
When is a public health problem a crisis? LA has the worst...
Remembering Thomas E. Kurtz
By MIKE MAGEE This has been a challenging week for me, but...
Twin Brothers Launch Seen Health with $22M to Provide Culturally-Focused Care for Seniors
Seen Health emerged from stealth on Monday. The company builds on the...
Leave a comment